Ignite Creation Date:
2025-12-24 @ 10:58 PM
Ignite Modification Date:
2025-12-26 @ 5:08 PM
Study NCT ID:
NCT00319969
Status:
COMPLETED
Last Update Posted:
2009-09-30
First Post:
2006-04-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
Sponsor:
Celgene Corporation
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CNF3140-SCLC-05004
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Kathy Knapp, Clinical Program Manager
Old Organization:
Pharmion Corporation